Brief: Geron Q2 EPS USD -0.02

Geron

06/08/2025 12:01

Overview

Geron Q2 product revenue rises to $49 mln, driven by RYTELO sales

Net loss narrows sharply to $16.4 mln, operating income beats estimates

Harout Semerjian appointed as new President and CEO

Outlook

Geron maintains 2025 operating expenses guidance of $270 mln to $285 mln

Company expects existing cash and RYTELO sales to fund operations

Geron plans RYTELO launch in select EU countries in 2026

IMpactMF trial full enrollment expected by year-end 2025

Result Drivers

RYTELO SALES - Achieved $49 mln in net product revenue for Q2 2025, a 24% increase from Q1, driven by increased demand from new patient starts

COMMERCIAL EXPANSION - Expanded sales team by 20% and doubled medical science liaisons to boost RYTELO adoption

EU LAUNCH PREPARATION - Preparing for RYTELO launch in select EU countries following recent approval

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$49.01 mln
Q2 EPS
-$0.02
Q2 Net Income
-$16.38 mln
Q2 Operating Income
Beat
-$12.45 mln
-$20 mln (9 Analysts)
Q2 Operating Expenses
$61.49 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Geron Corp is $4.00, about 70% above its August 5 closing price of $1.20

Press Release: ID:nBw8Yn88ba

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)